Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

John Mitchell to Neoplasm Staging

This is a "connection" page, showing publications John Mitchell has written about Neoplasm Staging.

 
Connection Strength
 
 
 
0.832
 
  1. Mitchell JD, Krasna MJ. The society of thoracic surgeons esophageal cancer guideline series. Ann Thorac Surg. 2013 Jul; 96(1):7.
    View in: PubMed
    Score: 0.322
  2. Varghese TK, Hofstetter WL, Rizk NP, Low DE, Darling GE, Watson TJ, Mitchell JD, Krasna MJ. The society of thoracic surgeons guidelines on the diagnosis and staging of patients with esophageal cancer. Ann Thorac Surg. 2013 Jul; 96(1):346-56.
    View in: PubMed
    Score: 0.081
  3. Schefter TE, Patel M, McCarter M, Kane M, Russ PD, Nash SR, Shah RJ, Mitchell JD. Triple-modality therapy for a woman with locally advanced thoracic esophageal adenocarcinoma, Part 2. Oncology (Williston Park). 2005 Jun; 19(7):830, 835-6, 838 passim.
    View in: PubMed
    Score: 0.046
  4. Schefter TE, Patel M, McCarter M, Kane M, Russ PD, Nash SR, Shah RJ, Mitchell JD. Triple-modality therapy for a woman with locally advanced thoracic esophageal adenocarcinoma, part 1. Oncology (Williston Park). 2005 May; 19(6):775-8, 783-4, 788 passim.
    View in: PubMed
    Score: 0.046
  5. Stuart CM, Mott NM, Bronsert MR, Randhawa SK, David EA, Mitchell JD, Meguid RA. The Association Between Sociodemographic Factors and Delays to Minimally Invasive Surgery for Stage IA-IIIA Non-small Cell Lung Cancer. Ann Thorac Surg. 2025 May; 119(5):1082-1091.
    View in: PubMed
    Score: 0.045
  6. Stinchcombe TE, Wang X, Damman B, Mentlick J, Landreneau R, Wigle D, Jones DR, Conti M, Ashrafi AS, Liberman M, de Perrot M, Mitchell JD, Keenan R, Bauer T, Miller D, Altorki N. Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer. J Clin Oncol. 2024 Apr 01; 42(10):1110-1113.
    View in: PubMed
    Score: 0.042
  7. Dyas AR, Bronsert MR, Stuart CM, Thomas MB, Schulick RD, Franco SR, Gleisner A, Randhawa SK, David EA, Mitchell JD, Meguid RA. Analyzing the impact of the Coronavirus disease 2019 pandemic on initial oncologic presentation and treatment of non-small cell lung cancer in the United States. J Thorac Cardiovasc Surg. 2024 Aug; 168(2):378-390.e7.
    View in: PubMed
    Score: 0.042
  8. Altorki N, Wang X, Damman B, Mentlick J, Landreneau R, Wigle D, Jones DR, Conti M, Ashrafi AS, Liberman M, de Perrot M, Mitchell JD, Keenan R, Bauer T, Miller D, Stinchcombe TE. Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance). J Thorac Cardiovasc Surg. 2024 01; 167(1):338-347.e1.
    View in: PubMed
    Score: 0.041
  9. Mitchell JD. Solitary fibrous tumor of the pleura. Semin Thorac Cardiovasc Surg. 2003 Jul; 15(3):305-9.
    View in: PubMed
    Score: 0.040
  10. Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, Port J, Jones DR, Conti M, Ashrafi AS, Liberman M, Yasufuku K, Yang S, Mitchell JD, Pass H, Keenan R, Bauer T, Miller D, Kohman LJ, Stinchcombe TE, Vokes E. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023 02 09; 388(6):489-498.
    View in: PubMed
    Score: 0.039
  11. Boffa DJ, Dhamija A, Kosinski AS, Kim AW, Detterbeck FC, Mitchell JD, Onaitis MW, Paul S. Fewer complications result from a video-assisted approach to anatomic resection of clinical stage I lung cancer. J Thorac Cardiovasc Surg. 2014 Aug; 148(2):637-43.
    View in: PubMed
    Score: 0.021
  12. Peled N, Hakim M, Bunn PA, Miller YE, Kennedy TC, Mattei J, Mitchell JD, Hirsch FR, Haick H. Non-invasive breath analysis of pulmonary nodules. J Thorac Oncol. 2012 Oct; 7(10):1528-33.
    View in: PubMed
    Score: 0.019
  13. Yu JA, Li H, Meng X, Fullerton DA, Nemenoff RA, Mitchell JD, Weyant MJ. Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells. J Thorac Cardiovasc Surg. 2012 Dec; 144(6):1479-85.
    View in: PubMed
    Score: 0.019
  14. Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, Felip E, Peylan-Ramu N, Gurpide A, Grannis FW, Mitchell JD, Tachdjian S, Swann RS, Huff A, Roychowdhury DF, Reeves A, Ottesen LH, Yankelevitz DF. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol. 2010 Jul 01; 28(19):3131-7.
    View in: PubMed
    Score: 0.016
  15. Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE, Landreneau RJ, Inculet RI, Jones DR, Meyers BF, Harpole DH, Putnam JB, Rusch VW. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006 Mar; 81(3):1013-9; discussion 1019-20.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)